Current Message	Return to posts
From: Hamsterwheel
More TRXplosive This business has developed a technology called dCELL which encourages cell growth via a scaffolding patch which is inserted into the designated area and attracts the body’s own cells to the wound area thus enabling the body to regenerate and repair itself without the need for further invasive activity. The technology can also be applied to heart valve replacement procedures where the new valve – sourced from pigs – is ‘stripped down’ by the dCELL technology and inserted into the patient. The new valve then undergoes a regenerative process using the patient’s own cells thus lowering the likelihood of rejection and infection. The global tissue heart valve market is worth $1.0bn+ so the potential is very big indeed. The interesting feature about the wound application is that it does not require a series of lengthy trials, submissions and approvals. As such, the company has already secured US distribution agreements for what will be known as DermaPure, entering into a market worth $1.4bn. The share priced did rise significantly on the back of the US deal – from 15p to 24p – but there is plenty more in the tank once revenues start to filter through from the US deals. Equally, we expect the NHS to adopt the dCELL wound product by the end of 2014 as a result of what appear to be already successful outcomes so far in current trial situations. If we had a banker bet for 2014, then this would be it. HTTP://www.thesmallcapfile.co.uk/utmeleven-for-2014/

You must log in or register before you can post messages (you'll be returned to this page once logged in).